Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jung, Seung Il | - |
dc.contributor.author | Kim, Myung Soo | - |
dc.contributor.author | Jeong, Chang Wook | - |
dc.contributor.author | Kwak, Cheol | - |
dc.contributor.author | Hong, Sung Kyu | - |
dc.contributor.author | Kang, Seok Ho | - |
dc.contributor.author | Joung, Jae Young | - |
dc.contributor.author | Lee, Seung Hwan | - |
dc.contributor.author | Yun, Seok Joong | - |
dc.contributor.author | Kim, Tae-Hwan | - |
dc.contributor.author | Park, Sung Woo | - |
dc.contributor.author | Jeon, Seong Soo | - |
dc.contributor.author | Kang, Minyong | - |
dc.contributor.author | Lee, Ji Youl | - |
dc.contributor.author | Chung, Byung Ha | - |
dc.contributor.author | Hong, Jun Hyuk | - |
dc.contributor.author | Ahn, Hanjong | - |
dc.contributor.author | Kim, Choung-Soo | - |
dc.contributor.author | Kwon, Dong Deuk | - |
dc.date.accessioned | 2021-08-31T15:09:25Z | - |
dc.date.available | 2021-08-31T15:09:25Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-01 | - |
dc.identifier.issn | 2466-0493 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/58531 | - |
dc.description.abstract | Purpose: This study aimed to evaluate the clinical efficacy of enzalutamide in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) patients using real-world data from Korean patients. Materials and Methods: We retrospectively reviewed the medical records of 199 chemotherapy-naive patients with mCRPC at 13 tertiary centers in Korea between 2014 and 2017. All patients received enzalutamide daily and 89 patients received concurrent androgen deprivation therapy (ADT). Results: The median age of the patients was 74 years. Initial results showed that 81.5% of the patients had Gleason score >= 8 and 33.3% of the patients had European Cooperative Oncology Group Performance Status 0. The overall mortality rate was 12%. The median OS was not archieved and 76.7% of patients were alive at 30 months. Median time until PSA progression was 6 months. The overall survival rate at 2 years was significantly higher (84.6% vs. 71.7%, p=0.015) and the duration of PSA progression-free survival was significantly longer (8.0 vs. 4.6 months, p=0.008) in patients receiving concurrent ADT than in those receiving enzalutamide alone. The incidence of adverse events of grade 3 or higher was 1.7%. Multivariate Cox proportional hazard analysis indicated that ADT administered concurrently with enzalutamide significantly improved the overall survival (hazard ratio, 0.346; 95% confidence interval, 0.125-0.958). Conclusions: Enzalutamide is effective and safe for chemotherapy-naive patients with mCRPC. Furthermore, the overall survival was significantly higher in patients receiving enzalutamide and concurrent ADT than in patients receiving enzalutamide alone. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN UROLOGICAL ASSOC | - |
dc.subject | ANDROGEN-DEPRIVATION THERAPY | - |
dc.subject | HORMONE AGONIST TREATMENT | - |
dc.subject | SERUM TESTOSTERONE | - |
dc.subject | CESSATION | - |
dc.subject | SURVIVAL | - |
dc.subject | RECOVERY | - |
dc.subject | TRIALS | - |
dc.subject | MEN | - |
dc.title | Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kang, Seok Ho | - |
dc.identifier.doi | 10.4111/icu.2020.61.1.19 | - |
dc.identifier.scopusid | 2-s2.0-85077941923 | - |
dc.identifier.wosid | 000506022000003 | - |
dc.identifier.bibliographicCitation | INVESTIGATIVE AND CLINICAL UROLOGY, v.61, no.1, pp.19 - 27 | - |
dc.relation.isPartOf | INVESTIGATIVE AND CLINICAL UROLOGY | - |
dc.citation.title | INVESTIGATIVE AND CLINICAL UROLOGY | - |
dc.citation.volume | 61 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 19 | - |
dc.citation.endPage | 27 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002548266 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.subject.keywordPlus | ANDROGEN-DEPRIVATION THERAPY | - |
dc.subject.keywordPlus | HORMONE AGONIST TREATMENT | - |
dc.subject.keywordPlus | SERUM TESTOSTERONE | - |
dc.subject.keywordPlus | CESSATION | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | RECOVERY | - |
dc.subject.keywordPlus | TRIALS | - |
dc.subject.keywordPlus | MEN | - |
dc.subject.keywordAuthor | Androgen antagonists | - |
dc.subject.keywordAuthor | Neoplasm metastasis | - |
dc.subject.keywordAuthor | Prostate neoplasms | - |
dc.subject.keywordAuthor | Treatment outcome | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.